These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 7602352

  • 21. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K, Nishiwaki Y, Sugiura T, Noda K, Mori K, Kawahara M, Negoro S, Watanabe K, Imamura F, Tamura T, Saijo N.
    Clin Cancer Res; 2005 Aug 01; 11(15):5534-8. PubMed ID: 16061870
    [Abstract] [Full Text] [Related]

  • 22. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI, Rivera F, Díaz-Puente MT, Lianes P, Colomer R, López-Brea M, López E, Paz-Ares L, Hitt R, García-Ribas I.
    J Natl Cancer Inst; 1995 Jun 07; 87(11):803-8. PubMed ID: 7540696
    [Abstract] [Full Text] [Related]

  • 23. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L.
    Ann Oncol; 1994 Oct 07; 5(8):709-16. PubMed ID: 7826903
    [Abstract] [Full Text] [Related]

  • 24. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
    Yau JC, Neidhart JA, Triozzi P, Verma S, Nemunaitis J, Quick DP, Mayernik DG, Oette DH, Haynes FA, Holcenberg J.
    Am J Hematol; 1996 Apr 07; 51(4):289-95. PubMed ID: 8602629
    [Abstract] [Full Text] [Related]

  • 25. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH, Bass D, Einhorn LH, Crawford J, Perez CA, Bartolucci A, Omura GA, Greco FA.
    J Clin Oncol; 1993 Jul 07; 11(7):1223-9. PubMed ID: 8391064
    [Abstract] [Full Text] [Related]

  • 26. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 07; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 27. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.
    Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S.
    J Clin Oncol; 1995 Dec 07; 13(12):2924-30. PubMed ID: 8523056
    [Abstract] [Full Text] [Related]

  • 28. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.
    Shea TC, Mason JR, Storniolo AM, Newton B, Breslin M, Mullen M, Ward DM, Miller L, Christian M, Taetle R.
    J Clin Oncol; 1992 Mar 07; 10(3):464-73. PubMed ID: 1740685
    [Abstract] [Full Text] [Related]

  • 29. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
    Thongprasert S.
    J Med Assoc Thai; 2000 May 07; 83(5):549-53. PubMed ID: 10863902
    [Abstract] [Full Text] [Related]

  • 30. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N.
    J Clin Oncol; 1995 Mar 07; 13(3):652-9. PubMed ID: 7533825
    [Abstract] [Full Text] [Related]

  • 31. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, Lee JS.
    J Clin Oncol; 2005 May 20; 23(15):3488-94. PubMed ID: 15908658
    [Abstract] [Full Text] [Related]

  • 32. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
    Hesketh PJ, McCoy J, Dunphy FR, Bearden JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR.
    J Thorac Oncol; 2006 Nov 20; 1(9):991-5. PubMed ID: 17409984
    [Abstract] [Full Text] [Related]

  • 33. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R.
    J Clin Oncol; 1994 Jun 20; 12(6):1251-8. PubMed ID: 8201386
    [Abstract] [Full Text] [Related]

  • 34. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC.
    J Clin Oncol; 2005 Nov 01; 23(31):7974-84. PubMed ID: 16258098
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS.
    J Clin Oncol; 1996 Nov 01; 14(11):2976-83. PubMed ID: 8918495
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T.
    J Clin Oncol; 1994 Sep 01; 12(9):1833-41. PubMed ID: 7521905
    [Abstract] [Full Text] [Related]

  • 39. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
    Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL.
    J Clin Oncol; 1997 Feb 01; 15(2):660-6. PubMed ID: 9053491
    [Abstract] [Full Text] [Related]

  • 40. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M, West Japan Thoracic Oncology Group 9902.
    J Clin Oncol; 2006 Nov 20; 24(33):5247-52. PubMed ID: 17114657
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.